In contrast, our previous study showed that treatment with a PRMT5 inhibitor significantly suppressed pressure overload-induced pathological cardiac hypertrophy, myocardial fibrosis, and left ventricular systolic dysfunction [27]. This evidence concerns the gene PRMT5 and cardiac hypertrophy.